到2034年，干眼症市场将出现惊人增长-动脉网

Dry Eye Disease Market to Observe Stupendous Growth by 2034

CISION 等信源发布 2025-01-29 06:31



可切换为仅中文







DelveInsight's analysis indicates a promising outlook for the dry eye disease market from 2024 to 2034, with positive growth anticipated. This growth trajectory is attributed to the emergence of numerous therapies in the pipeline set to launch within the forecast period.

DelveInsight的分析表明，从2024年到2034年，干眼病市场前景看好，预计会出现正增长。这种增长轨迹归因于在预测期内推出的众多疗法的出现。

LAS VEGAS

拉斯维加斯

Jan. 28, 2025

2025年1月28日

/PRNewswire/ -- DelveInsight's

/PRNewswire/--Delveinsight的

Dry Eye Disease Market Insights

干眼症市场洞察

report includes a comprehensive understanding of current treatment practices, dry eye disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [

该报告全面了解了当前的治疗方法、干眼病新兴药物、个体疗法的市场份额，以及2020年至2034年的当前和预测市场规模，细分为7MM[

the United States

美国

, the EU4 (

，EU4(

Germany

德国

France

法国

Italy

意大利

, and

，以及

Spain

西班牙

) and the

)

United Kingdom

英国

, and

，以及

Japan

日本

Key Takeaways from the Dry Eye Disease Market Report

干眼症市场报告的主要收获

According to DelveInsight's analysis, the market size for dry eye disease was found to be

根据DelveInsight的分析，干眼症的市场规模为

USD 3.7 billion

37亿美元

in the 7MM in 2023.

2023年的7毫米。

The United States

美国

accounted for the highest market size of DED ~

占据了DED的最高市场规模~

73%

of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (

与其他主要市场（即欧盟4国）相比，2023年的总市场规模为7MM(

Germany

德国

France

法国

Italy

意大利

, and

，以及

Spain

西班牙

), and the

)，以及

United Kingdom

英国

, and

，以及

Japan

日本

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly

在DelveInsight进行的评估中，估计在7MM内诊断出的DED流行病例总数接近

54.6 million

5460万

in 2023.

2023年。

Leading dry eye disease companies such as

领先的干眼症公司，如

Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co.

Palatin Technologies，Inc.，Aldeyra Therapeutics，Inc.，ReGenTree，RegeneRx Biopharmaceuticals，Inc.，Mimetogen，Alcon，Aerie Pharmaceuticals，BRIM Biotechnology，Inc.，Seikagaku Corporation，Mitotech，Senju Pharmaceuticals，Sylentis，S.A.，PharmaMar，Stuart Therapeutics，VivaVision Biotech，HanAll BioPharma Co.，Ltd.，Daewoong Pharmaceuticals。

Ltd., Redwood Pharma AB, OKYO Pharma, AxeroVision, Inc., Glaukos Corporation, Oculis,.

有限公司，红木制药公司，OKYO制药公司，AxeroVision，Inc.，Glaukos公司，Oculis。

and others are developing novel dry eye disease drugs that can be available in the dry eye disease market in the coming years.

其他人正在开发新的干眼症药物，这些药物可以在未来几年的干眼症市场上买到。

The promising dry eye disease therapies in the pipeline include

正在开发的有前途的干眼症疗法包括

PL9643，Reproxalap，RGN-259（Tß4），他维利米（MIM-D3），AR-15512，BRM421，SI-614，SkQ1滴眼液，SJP-0132，Tivanisiran（SYL1001），ST-100（Vezocolmitide），VVN001，Tanfanercept眼科溶液/HL036，

RP101

, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02),

，AXR-270（乳膏），OK-101，AXR-270，AXR-159，GLK-301（毛果芸香碱眼科外用乳膏），Licaminlimab（OCS-02），

and others.

和其他人。

Discover which therapies are expected to grab the major dry eye disease market share @

发现哪些疗法有望抢占干眼症的主要市场份额@

Dry Eye Disease Market Report

干眼病市场报告

Dry Eye Disease Overview

干眼症概述

Dry eye disease (DED) is a common chronic condition characterized by inadequate tear production or excessive tear evaporation, leading to inflammation and damage to the eye's surface. Causes of DED are multifactorial and include aging, hormonal changes, prolonged screen use, environmental factors (dry climates, wind), certain medications, autoimmune conditions, and contact lens wear.

干眼症（DED）是一种常见的慢性病，其特征是泪液产生不足或泪液蒸发过度，导致炎症和眼表损伤。DED的原因是多因素的，包括衰老，激素变化，长时间使用屏幕，环境因素（干燥气候，风），某些药物，自身免疫状况和隐形眼镜磨损。

Symptoms often include persistent dryness, redness, irritation, a gritty or sandy sensation, sensitivity to light, blurry vision, and in some cases, paradoxical excessive tearing..

症状通常包括持续干燥、发红、发炎、砂砾或沙质感觉、对光线敏感、视力模糊，在某些情况下还包括反常的过度撕裂。。

Diagnosing DED typically involves a thorough eye examination by an ophthalmologist or optometrist. Common diagnostic tests include the Schirmer test, tear breakup time, and ocular surface staining with dyes such as fluorescein or lissamine green to detect surface damage. Early diagnosis and management are essential to prevent complications like corneal damage and vision impairment..

诊断DED通常需要眼科医生或验光师进行彻底的眼部检查。常见的诊断测试包括Schirmer测试，泪液破裂时间以及用荧光素或赖氨酸绿等染料进行眼表染色以检测表面损伤。早期诊断和管理对于预防角膜损伤和视力障碍等并发症至关重要。。

Dry Eye Disease Epidemiology Segmentation

干眼病流行病学细分

The dry eye disease epidemiology section provides insights into the historical and current dry eye disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

干眼病流行病学部分提供了对历史和当前干眼病患者库的见解，并预测了7MM的趋势。通过探索大量研究和关键意见领袖的观点，它有助于识别当前和预测患者趋势的原因。

The dry eye disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

《干眼病市场报告》提供了2020-2034年研究期间7MM范围内的流行病学分析，分为：

Total Diagnosed Prevalent Cases

确诊流行病例总数

Gender-specific Diagnosed Prevalent Cases

性别特异性诊断流行病例

Age-specific Diagnosed Prevalent Cases

年龄特异性诊断流行病例

Severity-specific Diagnosed Prevalent Cases

严重程度特定的诊断流行病例

Dry Eye Disease Treatment Market

干眼症治疗市场

Pharmacological treatments play a pivotal role in the comprehensive management of dry eye disease. Common solutions like artificial tears provide quick relief by enhancing the tear film, while prescription medications such as cyclosporine (e.g.,

药物治疗在干眼症的综合管理中起着关键作用。人工泪液等常见解决方案通过增强泪膜来快速缓解，而环孢素等处方药（例如。，

RESTASIS

剩余

) and lifitegrast (e.g.,

)和lifitegrast（例如。，

XIIDRA

) help alleviate symptoms through their anti-inflammatory effects. Recently approved therapies, including

)通过抗炎作用帮助缓解症状。最近批准的疗法，包括

VEVYE

我们

(cyclosporine ophthalmic solution)/CyclASol and

（环环环（ CyclASol and）

MIEBO

米博

(NOV03), offer new and promising options.

（2003年11月），提供了新的和有前途的选择。

Beyond pharmacological approaches, other strategies for managing DED include in-office treatments like intense pulsed light therapy and meibomian gland expression, as well as eyelid care techniques such as warm compresses and lid scrubs. For more severe cases, lifestyle changes, punctal plugs, or scleral contact lenses may be considered to provide additional symptom relief..

除药理学方法外，管理DED的其他策略还包括办公室内治疗，如强脉冲光疗法和睑板腺表达，以及眼睑护理技术，如温热按压和眼睑擦洗。对于更严重的病例，可以考虑改变生活方式，点状塞或巩膜隐形眼镜来缓解症状。。

The eye drop market is largely focused on alleviating dry eye symptoms using moisturizing agents such as hyaluronic acid. However, there is a notable gap in effective treatments for viral keratoconjunctivitis, a condition often mismanaged with antibiotics. Marinomed Biotech AG's MAM-1001-3 eye drops aim to address this need by leveraging Carragelose, a red seaweed-derived polymer with exceptional moisturizing and broad-spectrum antiviral properties. .

滴眼液市场主要集中在使用透明质酸等保湿剂缓解干眼症。然而，在病毒性角结膜炎的有效治疗方面存在显着差距，这种疾病通常与抗生素管理不当。Marinomed Biotech AG的MAM-1001-3滴眼液旨在通过利用Carragelose来满足这一需求，Carragelose是一种红色海藻衍生的聚合物，具有出色的保湿和广谱抗病毒特性。。

Classified as a medical device and in the pre-launch phase with MDD certification, MAM-1001-3 provides dual benefits: soothing dry, irritated eyes and potentially offering a targeted solution for viral keratoconjunctivitis, thereby advancing patient care in ocular health. In summary, implementing a personalized combination of these management strategies can effectively reduce symptoms and enhance the quality of life for individuals with DED..

MAM-1001-3被归类为医疗器械，在MDD认证的上市前阶段，具有双重益处：缓解干燥，刺激的眼睛，并可能为病毒性角结膜炎提供靶向解决方案，从而促进患者眼部健康护理。总之，实施这些管理策略的个性化组合可以有效减轻症状，提高DED患者的生活质量。。

To know more about dry eye disease treatment guidelines, visit @

要了解更多有关干眼症治疗指南的信息，请访问@

Dry Eye Disease Management

Dry Eye Disease Pipeline Therapies and Key Companies

干眼症管道疗法和关键公司

PL9643: Palatin Technologies, Inc.

PL9643:Palatin Technologies，Inc。

Reproxalap: Aldeyra Therapeutics, Inc.

Reproxalap:Aldeyra Therapeutics，Inc。

RGN-259 (Tß4): ReGenTree/RegeneRx Biopharmaceuticals, Inc.

RGN-259（Tß4）：ReGenTree/RegeneRx生物制药，股份有限公司。

Tavilermide (MIM-D3): Mimetogen

表长度（MIM-D3）： Mimetogen

AR-15512: Alcon/Aerie Pharmaceuticals

AR-15512：艾尔康/艾瑞制药公司

BRM421: BRIM Biotechnology, Inc.

BRM421:BRIM Biotechnology，Inc。

SI-614: Seikagaku Corporation

SI-614：精工公司

SkQ1 eye drops: Mitotech

SJP-0132: Senju Pharmaceutical

SJP-0132：森州制药

Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar

蒂瓦尼西兰（SYL1001）：Sylentis，S.A./PharmaMar

ST-100 (Vezocolmitide): Stuart Therapeutics

ST-100（维佐克米特）：斯图尔特治疗公司

VVN001: VivaVision Biotech

Tanfanercept Ophthalmic Solution/HL036: HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd.

Tanfanercept 眼科解决方案/HL036:汉全生物制药有限公司/大宇制药有限公司

RP101

: Redwood Pharma AB

：红木制药公司

AXR-270 (cream): AxeroVision, Inc.

AXR-270（奶油）：AxeroVision，Inc。

OK-101: OKYO Pharma

OK-101：OKYO制药

AXR-270: AxeroVision, Inc.

AXR-270:AxeroVision，股份有限公司。

AXR-159: AxeroVision, Inc.

AXR-159：AxeroVision, Inc.

GLK-301 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation

GLK-301（毛果芸香碱眼用外用乳膏）：Glaukos Corporation

Licaminlimab (OCS-02): Oculis

利卡明利单抗（OCS-02）：奥库利斯

Discover more about dry eye disease drugs in development @

了解更多正在开发的干眼症药物@

Dry Eye Disease Clinical Trials

干眼病临床试验

Dry Eye Disease Market Dynamics

干眼症市场动态

The dry eye disease market dynamics are expected to change in the coming years. Dry eye is a highly prevalent condition, especially among the

干眼病市场动态预计在未来几年会发生变化。干眼症是一种非常普遍的疾病，尤其是在

aging population

人口老龄化

, creating a substantial need for effective diagnosis, treatment, and management solutions. Current treatment options, such as

，对有效的诊断，治疗和管理解决方案产生了巨大的需求。当前的治疗选择，例如

artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs

人工泪液、处方药、眼睑卫生产品和泪点塞

, enable tailored approaches to address the condition. Increased public education campaigns can

，可以采用量身定制的方法来解决这种情况。

raise awareness

提高认识

and encourage individuals to seek help, while

鼓励个人寻求帮助，同时

collaboration among pharmaceutical companies

制药公司之间的合作

, research institutions, and healthcare providers can drive the development of novel therapies and diagnostic tools for dry eye disease.

，研究机构和医疗保健提供者可以推动干眼症新疗法和诊断工具的开发。

Furthermore, potential therapies are being investigated for the treatment of dry eye disease, and it is safe to predict that the treatment space will significantly impact the dry eye disease market during the forecast period. Moreover, the

此外，正在研究治疗干眼症的潜在疗法，可以安全地预测，在预测期间，治疗空间将对干眼症市场产生重大影响。

anticipated introduction of emerging therapies

预期引入新兴疗法

with improved efficacy and a further

疗效提高，进一步

improvement in the diagnosis rate

提高诊断率

are expected to drive the growth of the dry eye disease market in the 7MM.

。

However, several factors may impede the growth of the dry eye disease market. Some dry eye treatments, particularly prescription medications, can cause

然而，有几个因素可能会阻碍干眼症市场的增长。一些干眼症治疗，特别是处方药，可能会导致

side effects like blurred vision or itching

副作用，如视力模糊或瘙痒

, while the

，而

cost of treatment

治疗费用

, including medications and frequent healthcare visits, can be burdensome for patients; additionally,

，包括药物治疗和频繁的医疗就诊，可能会给患者带来负担；另外，

intense market competition increases pricing pressures

激烈的市场竞争增加了定价压力

and marketing expenditures for companies, and failure to properly diagnose or treat dry eye may lead to disease progression and complications, significantly impacting patient health and well-being.

和公司的营销支出，以及未能正确诊断或治疗干眼症可能导致疾病进展和并发症，严重影响患者的健康和福祉。

Moreover, dry eye disease treatment poses a

此外，干眼症的治疗构成了

significant economic burden

重大经济负担

and disrupts patients' overall well-being and QOL. Furthermore, dry eye disease market growth may be offset by

并破坏患者的整体幸福感和生活质量。此外，干眼症市场的增长可能会被

failures and discontinuation of emerging therapies

新兴疗法的失败和中断

unaffordable pricing

无法承受的定价

market access and reimbursement issues

市场准入和报销问题

, and a

，以及

shortage of healthcare specialists

保健专家短缺

. In addition, the

此外

undiagnosed, unreported cases and the unawareness

未确诊，未报告的病例和不知情

about the disease may also impact dry eye disease market growth.

关于该疾病也可能影响干眼症市场的增长。

Dry Eye Disease Market Report Metrics

干眼病市场报告指标

Details

详细信息

Study Period

研究期间

2020–2034

Coverage

覆盖范围

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

7MM [美国、欧盟四国（德国、法国、意大利和西班牙）以及英国和日本]。

Dry Eye Disease Market Size in 2023

2023年干眼病市场规模

USD 3.7 Billion

37亿美元

Key Dry Eye Disease Companies

主要干眼症公司

Ltd., Redwood Pharma AB, OKYO Pharma, AxeroVision, Inc., Glaukos Corporation, Oculis, and others.

有限公司，Redwood Pharma AB，OKYO Pharma，AxeroVision，Inc.，Glaukos Corporation，Oculis等。

Key Pipeline Dry Eye Disease Therapies

关键管道干眼症疗法

PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others.

PL9643，Reproxalap，RGN-259（Tß4），他维勒米（MIM-D3），AR-15512，BRM421，SI-614，SkQ1滴眼液，SJP-0132，Tivanisiran（SYL1001），ST-100（Vezocolmitide），VVN001，坦凡那西普眼科溶液/HL036，RP101，AXR-270（乳膏），OK-101，AXR-270，AXR-159，GLK-301（毛果芸香碱眼科外用乳膏），利卡米尼单抗（OCS-02）等。

Scope of the

的范围

Dry Eye Disease

干眼症

Market Report

市场报告

Therapeutic Assessment:

治疗评估：

Dry Eye Disease current marketed and emerging therapies

干眼症目前上市和新兴疗法

Dry Eye Disease

干眼症

Market Dynamics:

市场动态：

Key Market Forecast Assumptions of Emerging Dry Eye Disease Drugs and Market Outlook

新兴干眼症药物的主要市场预测假设和市场前景

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

Unmet Needs, KOL's views, Analyst's views, Dry Eye Disease Market Access and Reimbursement

未满足的需求、KOL的观点、分析师的观点、干眼症市场准入和报销

Download the report to understand which factors are driving dry eye disease market trends @

下载该报告以了解哪些因素推动了干眼症的市场趋势@

Dry Eye Disease Market Trends

干眼症市场趋势

Table of Contents

Key Insights

关键见解

Report Introduction

报告简介

Dry Eye Disease (DED) Market Overview at a Glance

干眼症（DED）市场概览

3.1

Market Share (%) Distribution by Therapies of DED in 2020

2020年DED疗法的市场份额（%）分布

3.2

Market Share (%) Distribution by Therapies of DED in 2034

2034年DED治疗的市场份额（%）分布

Epidemiology and Market Methodology of DED

DED的流行病学和市场方法

Executive Summary of Dry Eye Disease (DED)

干眼症（DED）执行摘要

Key Events

关键事件

Disease Background and Overview

疾病背景和概述

7.1

Introduction

简介

7.2

Tear Film Working

泪膜加工

7.3

Etiology

病因

7.4

Risk Factors

风险因素

7.5

Pathophysiology

病理生理学

7.6

Symptoms and Clinical Presentations

症状和临床表现

7.7

Diagnosis

诊断

7.7.1

Diagnostic Criteria

诊断标准

7.7.1.1

Comparison of Dry Eye Definition and Diagnostic Criteria between JDES/ADES and DEWS II

JDES/ADES和DEWS II干眼症定义和诊断标准的比较

7.7.1.2

Diagnostic Criteria of the JDES, 1995 Version

1995年版JDES诊断标准

7.7.1.3

Diagnostic criteria of DED proposed by the JDES (2006 version)

JDES（2006版）提出的DED诊断标准

7.7.2

Differential Diagnosis

鉴别诊断

7.7.3

Diagnostic Algorithm

诊断算法

7.7.4

Diagnostic Scheme

诊断方案

7.7.5

Diagnostic Guidelines

诊断指南

7.7.5.1

Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology

美国眼科学会干眼综合征首选实践模式指南

7.8

Treatment and Management

7.8.1

Treatment Algorithm

治疗算法

7.8.2

Treatment Guidelines

治疗指南

7.8.2.1

TFOS DEWS II Management and Therapy Guidelines

TFOS DEWS II管理和治疗指南

7.8.2.2

Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology

美国眼科学会干眼综合征首选实践模式指南

Epidemiology and Patient Population

流行病学和患者人群

8.1

Key Findings

主要调查结果

8.2

Assumptions and Rationale: The 7MM

假设和理由：7MM

8.2.1

Diagnosed Prevalence of DED

诊断出的DED患病率

8.2.2

Gender-specific Prevalence of DED

DED的性别特异性患病率

8.2.3

Age-specific Diagnosed Prevalence of DED

DED的年龄特异性诊断患病率

8.2.4

Severity-specific Diagnosed Prevalence of DED

严重程度特定的DED诊断患病率

8.3

Total Diagnosed Prevalent Cases of DED in the 7MM

7MM内确诊的DED流行病例总数

8.4

The United States

美国

8.4.1

Total Diagnosed Prevalent Cases of DED

诊断出的DED流行病例总数

8.4.2

Gender-specific Diagnosed Prevalent Cases of DED

性别特异性诊断的DED流行病例

8.4.3

Age-specific Diagnosed Prevalent Cases of DED

年龄特异性诊断的DED流行病例

8.4.4

Severity-specific Diagnosed Prevalent Cases of DED

严重程度特异性诊断的DED流行病例

8.5

EU4 and the UK

EU4和英国

8.5.1

Germany

德国

8.5.1.1

Total Diagnosed Prevalent Cases of DED in Germany in Germany

德国DED确诊流行病例总数

8.5.1.2

Gender-specific Diagnosed Prevalent Cases of DED in Germany

8.5.1.3

Age-specific Diagnosed Prevalent Cases of DED in Germany

8.5.1.4

Severity-specific Diagnosed Prevalent Cases of DED in Germany

德国特定严重程度诊断的DED流行病例

8.5.2

France

法国

8.5.2.1

Total Diagnosed Prevalent Cases of DED in France

法国确诊的DED流行病例总数

8.5.2.2

Gender-specific Diagnosed Prevalent Cases of DED in France

法国按性别诊断的DED流行病例

8.5.2.3

Age-specific Diagnosed Prevalent Cases of DED in France

法国特定年龄段确诊的DED流行病例

8.5.2.4

Severity-specific Diagnosed Prevalent Cases of DED in France

法国特定严重程度诊断的DED流行病例

8.5.3

Italy

意大利

8.5.3.1

Total Diagnosed Prevalent Cases of DED in Italy

意大利确诊的DED流行病例总数

8.5.3.2

Gender-specific Diagnosed Prevalent Cases of DED in Italy

意大利按性别诊断的DED流行病例

8.5.3.3

Age-specific Diagnosed Prevalent Cases of DED in Italy

意大利特定年龄段确诊的DED流行病例

8.5.3.4

Severity-specific Diagnosed Prevalent Cases of DED in Italy

意大利特定严重程度的DED流行病例

8.5.4

Spain

西班牙

8.5.4.1

Total Diagnosed Prevalent Cases of DED in Spain

西班牙确诊的DED流行病例总数

8.5.4.2

Gender-specific Diagnosed Prevalent Cases of DED in Spain

西班牙按性别诊断的DED流行病例

8.5.4.3

Age-specific Diagnosed Prevalent Cases of DED in Spain

西班牙特定年龄段确诊的DED流行病例

8.5.4.4

Severity-specific Diagnosed Prevalent Cases of DED in Spain

西班牙特定严重程度诊断的DED流行病例

8.5.5

The United Kingdom

英国

8.5.5.1

Total Diagnosed Prevalent Cases of DED in the UK

英国诊断出的DED流行病例总数

8.5.5.2

Gender-specific Diagnosed Prevalent Cases of DED in the UK

英国按性别诊断的DED流行病例

8.5.5.3

Age-specific Diagnosed Prevalent Cases of DED in the UK

英国特定年龄段确诊的DED流行病例

8.5.5.4

Severity-specific Diagnosed Prevalent Cases of DED in the UK

英国特定严重程度的DED流行病例

8.6

Japan

日本

8.6.1

Total Diagnosed Prevalent Cases of DED

诊断出的DED流行病例总数

8.6.2

Gender-specific Diagnosed Prevalent Cases of DED

性别特异性诊断的DED流行病例

8.6.3

Age-specific Diagnosed Prevalent Cases of DED in the US

美国特定年龄段确诊的DED流行病例

8.6.4

Severity-specific Diagnosed Prevalent Cases of DED

严重程度特异性诊断的DED流行病例

Patient Journey

患者旅程

Marketed Therapies

上市疗法

10.1

Key Cross Competition of Marketed Therapies

市场疗法的关键交叉竞争

10.2

CEQUA (cyclosporine ophthalmic solution) 0.09%: Sun Pharm

CEQUA（环孢素眼用溶液）0.09%：Sun Pharm

10.2.1

Product Description

产品描述

10.2.2

Regulatory Approval

10.2.3

Other Developmental Activities

其他发展活动

10.2.4

Clinical Development

临床开发

10.2.5

Clinical Trials Information

临床试验信息

10.2.6

Safety and Efficacy

安全性和有效性

10.2.7

Product Profile

产品简介

10.3

TYRVAYA (varenicline solution): OYSTER POINT PHARMA

TYRVAYA（伐尼克兰溶液）：奥斯特点制药

10.3.1

Product Description

产品描述

10.3.2

Regulatory Approval

监管部门批准

10.3.3

Other Developmental Activities

其他发展活动

10.3.4

Clinical Development

临床开发

10.3.5

Clinical Trials Information

临床试验信息

10.3.6

Safety and Efficacy

安全性和有效性

10.3.7

Product Profile

产品简介

10.4

EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%: ALCON LABS INC/Kala Pharmaceuticals

EYSUVIS（洛捷普诺埃塔邦酸眼科悬浮液）0.25%：ALCON LABS INC/Kala Pharmaceuticals

10.4.1

Product Description

产品描述

10.4.2

Regulatory Approvals

监管机构批准

10.4.3

Other Developmental Activities

其他发展活动

10.4.4

Clinical Development

临床开发

10.4.5

Clinical Trials Information

临床试验信息

10.4.6

Safety and Efficacy

安全性和有效性

10.4.7

Product Profile

产品简介

10.5

VEVYE (cyclosporine ophthalmic solution)/ CyclASol: Novaliq/ Harrow Eye

VEVYE（环孢素眼用溶液）/环己醇：诺瓦利克/哈罗眼

10.5.1

Product Description

产品描述

10.5.2

Regulatory Approvals

监管机构批准

10.5.3

Other Developmental Activities

其他发展活动

10.5.4

Clinical Development

临床开发

10.5.5

Clinical Trials Information

临床试验信息

10.5.6

Safety and Efficacy

安全性和有效性

10.5.7

Product Profile

产品简介

10.6

MIEBO (NOV03): Bausch & Lomb Incorporated/Novaliq

MIEBO（NOV03）：Bausch & Lomb Incorporated/Novaliq

10.6.1

Product Description

产品描述

10.6.2

Regulatory Approval

监管部门批准

10.6.3

Other Developmental Activities

其他发展活动

10.6.4

Clinical Development

临床开发

10.6.5

Clinical Trials Information

临床试验信息

10.6.6

Safety and Efficacy

安全性和有效性

10.6.7

Product Profile

产品简介

Emerging Therapies

新兴疗法

11.1

Key Cross Competition of Emerging Therapies

新兴疗法的关键交叉竞争

11.2

PL9643: Palatin Technologies, Inc.

PL9643:Palatin Technologies，Inc。

11.2.1

Product Description

产品描述

11.2.2

Other Developmental Activities

其他发展活动

11.2.3

Clinical Development

临床开发

11.2.4

Clinical Trials Information

临床试验信息

11.2.5

Safety and Efficacy

安全性和有效性

11.2.6

Product Profile

产品简介

11.2.7

Analyst View

分析师视图

11.3

Reproxalap: Aldeyra Therapeutics, Inc.

Reproxalap:Aldeyra Therapeutics，Inc。

11.3.1

Product Description

产品描述

11.3.2

Other Developmental Activities

其他发展活动

11.3.3

Clinical Development

临床开发

11.3.4

Clinical Trials Information

临床试验信息

11.3.5

Safety and Efficacy

安全性和有效性

11.3.6

Product Profile

产品简介

11.3.7

Analyst Views

分析师视图

11.4

RGN-259 (Tβ4): ReGenTree/RegeneRx Biopharmaceuticals, Inc.

RGN-259（Tβ4）：ReGenTree/RegeneRx Biopharmaceuticals，Inc。

11.4.1

Product Description

产品描述

11.4.2

Other Developmental Activities

其他发展活动

11.4.3

Clinical Development

临床开发

11.4.4

Clinical Trials Information

临床试验信息

11.4.5

Safety and Efficacy

安全性和有效性

11.4.6

Product Profile

产品简介

11.4.7

Analyst Views

分析师视图

11.5

Tavilermide (MIM-D3): Mimetogen

表长度（MIM-D3）： Mimetogen

11.5.1

Product Description

产品描述

11.5.2

Other Developmental Activities

其他发展活动

11.5.3

Clinical Development

临床开发

11.5.4

Clinical Trials Information

临床试验信息

11.5.5

Safety and Efficacy

安全性和有效性

11.5.6

Product Profile

产品简介

11.5.7

Analyst Views

分析师视图

11.6

AR-15512: Alcon/Aerie Pharmaceuticals

AR-15512：艾尔康/艾瑞制药公司

11.6.1

Product Profile

产品简介

11.6.2

Other Developmental Activities

其他发展活动

11.6.3

Clinical Development

临床开发

11.6.4

Clinical Trials Information

临床试验信息

11.6.5

Safety and Efficacy

安全性和有效性

11.6.6

Product Profile

产品简介

11.6.7

Analyst Views

分析师视图

11.7

BRM421: BRIM Biotechnology, Inc.

BRM421:BRIM Biotechnology，Inc。

11.7.1

Product Description

产品描述

11.7.2

Other Developmental Activities

其他发展活动

11.7.3

Clinical Development

临床开发

11.7.4

Clinical Trials Information

临床试验信息

11.7.5

Safety and Efficacy

安全性和有效性

11.7.6

Product Profile

产品简介

11.7.7

Analyst Views

分析师视图

11.8

SI-614: Seikagaku Corporation

SI-614：精工公司

11.8.1

Product Description

产品描述

11.8.2

Other Developmental Activities

其他发展活动

11.8.3

Clinical Development

临床开发

11.8.4

Clinical Trials Information

临床试验信息

11.8.5

Product Profile

产品简介

11.8.6

Analyst Views

分析师视图

11.9

SkQ1 eye drops: Mitotech

SkQ1滴眼液：Mitotech

11.9.1

Product Description

产品描述

11.9.2

Other Developmental Activities

其他发展活动

11.9.3

Clinical Development

临床开发

11.9.4

Clinical Trials Information

临床试验信息

11.9.5

Safety and Efficacy

安全性和有效性

11.9.6

Product Profile

产品简介

11.9.7

Analysts' Views

分析师的观点

11.10

SJP-0132: Senju Pharmaceutical

SJP-0132：森州制药

11.10.1

Product Description

产品描述

11.10.2

Other Developmental Activities

其他发展活动

11.10.3

Clinical Development

临床开发

11.10.4

Clinical Trials Information

临床试验信息

11.10.5

Safety and Efficacy

安全性和有效性

11.10.6

Product Profile

产品简介

11.10.7

Analysts' Views

分析师的观点

11.11

Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar

蒂瓦尼西兰（SYL1001）：Sylentis，S.A./PharmaMar

11.11.1

Product Description

产品描述

11.11.2

Other Developmental Activities

其他发展活动

11.11.3

Clinical Development

临床开发

11.11.4

Clinical Trials Information

临床试验信息

11.11.5

Safety and Efficacy

安全性和有效性

11.11.6

Product Profile

产品简介

11.11.7

Analysts' Views

分析师的观点

11.12

ST-100 (Vezocolmitide): Stuart Therapeutics

ST-100（Vezocolmitide）：Stuart Therapeutics

11.12.1

Product Description

产品描述

11.12.2

Other Developmental Activities

其他发展活动

11.12.3

Clinical Development

临床开发

11.12.4

Clinical Trials Information

临床试验信息

11.12.5

Safety and Efficacy

安全性和有效性

11.12.6

Product Profile

产品简介

11.12.7

Analysts' Views

分析师的观点

11.13

VVN001: VivaVision Biotech

11.13.1

Product Description

产品描述

11.13.2

Other Developmental Activities

其他发展活动

11.13.3

Clinical Development

临床开发

11.13.4

Clinical Trials Information

临床试验信息

11.13.5

Safety and Efficacy

安全性和有效性

11.13.6

Product Profile

产品简介

11.13.7

Analysts' Views

分析师的观点

11.14

Tanfanercept Ophthalmic Solution/HL036: HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd.

Tanfanercept 眼科解决方案/HL036:汉全生物制药有限公司/大宇制药有限公司

11.14.1

Product Description

产品描述

11.14.2

Other Developmental Activities

其他发展活动

11.14.3

Clinical Development

临床开发

11.14.4

Clinical Trials Information

临床试验信息

11.14.5

Safety and Efficacy

安全性和有效性

11.14.6

Product Profile

产品简介

11.14.7

Analysts' Views

分析师的观点

11.15

RP101: Redwood Pharma AB

RP101：红木制药公司

11.15.1

Product Description

产品描述

11.15.2

Other Developmental Activities

其他发展活动

11.15.3

Clinical Development

临床开发

11.15.4

Clinical Trials Information

临床试验信息

11.15.5

Safety and Efficacy

安全性和有效性

11.15.6

Product Profile

产品简介

11.15.7

Analysts' Views

分析师的观点

11.16

AXR-270 (cream): AxeroVision, Inc.

AXR-270（奶油）：AxeroVision，Inc。

11.16.1

Product Description

产品描述

11.16.2

Clinical Development

临床开发

11.16.3

Clinical Trials Information

临床试验信息

11.16.4

Safety and Efficacy

安全性和有效性

11.16.5

Product Profile

产品简介

11.16.6

Analyst Views

分析师视图

11.17

OK-101: OKYO Pharma

OK-101：OKYO制药

11.17.1

Product Description

产品描述

11.17.2

Other Developmental Activities

其他发展活动

11.17.3

Clinical Development

临床开发

11.17.4

Clinical Trials Information

临床试验信息

11.17.5

Safety and Efficacy

安全性和有效性

11.17.6

Product Profile

产品简介

11.17.7

Analyst Views

分析师视图

11.18

AXR-270: AxeroVision, Inc.

AXR-270：AxeroVision, Inc.

11.18.1

Product Description

产品描述

11.18.2

Other Developmental Activities

其他发展活动

11.18.3

Clinical Development

临床开发

11.18.4

Clinical Trials Information

临床试验信息

11.18.5

Safety and Efficacy

安全性和有效性

11.18.6

Product Profile

产品简介

11.18.7

Analyst Views

分析师视图

11.19

AXR-159: AxeroVision, Inc.

AXR-159:AxeroVision，股份有限公司。

11.19.1

Product Description

产品描述

11.19.2

Other Developmental Activities

其他发展活动

11.19.3

Clinical Development

临床开发

11.19.4

Clinical Trials Information

临床试验信息

11.19.5

Safety and Efficacy

安全性和有效性

11.19.6

Product Profile

产品简介

11.19.7

Analyst Views

分析师视图

11.20

GLK-301 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation

GLK-301（毛果芸香碱眼用外用乳膏）：Glaukos Corporation

11.20.1

Product Description

产品描述

11.20.2

Other Developmental Activities

其他发展活动

11.20.3

Clinical Development

临床开发

11.20.4

Clinical Trials Information

临床试验信息

11.20.5

Safety and Efficacy

安全性和有效性

11.20.6

Product Profile

产品简介

11.20.7

Analyst Views

分析师视图

11.21

Licaminlimab (OCS-02): Oculis

利卡明利单抗（OCS-02）：奥库利斯

11.21.1

Product Description

产品描述

11.21.2

Other Developmental Activities

其他发展活动

11.21.3

Clinical Development

临床开发

11.21.4

Clinical Trials Information

临床试验信息

11.21.5

Safety and Efficacy

安全性和有效性

11.21.6

Product Profile

产品简介

11.21.7

Analyst Views

分析师视图

DED: Market Analysis

DED：市场分析

12.1

Key Findings

主要调查结果

12.2

Key Market Forecast Assumptions

12.3

Market Outlook

市场前景

12.4

Conjoint Analysis

联合分析

12.5

Total Market Size of DED in the 7MM

DED在7MM内的总市场规模

12.6

Market Size of DED by Therapies in the 7MM

DED的市场规模为7MM

12.7

Market Size of DED in the United States

美国DED的市场规模

12.7.1

Total Market Size of DED in the United States

美国DED的总市场规模

12.7.2

Market Size of DED by Therapies

DED治疗的市场规模

12.8

Market Size of DED in EU4 and the UK

欧盟4国和英国DED的市场规模

12.8.1

Germany

德国

12.8.1.1

Total Market Size of DED

DED的总市场规模

12.8.1.2

Market Size of DED by Therapies

DED治疗的市场规模

12.8.2

France

法国

12.8.2.1

Total Market Size of DED

DED的总市场规模

12.8.2.2

Market Size of DED by Therapies

DED治疗的市场规模

12.8.3

Italy

意大利

12.8.3.1

Total Market Size of DED

DED的总市场规模

12.8.3.2

Market Size of DED by Therapies

DED治疗的市场规模

12.8.4

Spain

西班牙

12.8.4.1

Total Market Size of DED

DED的总市场规模

12.8.4.2

Market Size of DED by Therapies

DED治疗的市场规模

12.8.5

The United Kingdom

英国

12.8.5.1

Total Market Size of DED

DED的总市场规模

12.8.5.2

Market Size of DED by Therapies

DED治疗的市场规模

12.9

Market Size of DED in Japan

日本DED的市场规模

12.9.1

Total Market Size of DED

DED的总市场规模

12.9.2

Market Size of DED by Therapies in Japan

日本DED治疗的市场规模

Key Opinion Leaders' Views

关键意见领袖的观点

SWOT Analysis

SWOT分析

Unmet Needs

未满足的需求

Market Access and Reimbursement

市场准入和报销

16.1

The United States

美国

16.1.1

Center for Medicare and Medicaid Services (CMS)

医疗保险和医疗补助服务中心（CMS）

16.2

In EU4 and the UK

在欧盟4国和英国

16.2.1

Germany

德国

16.2.2

France

法国

16.2.3

Italy

意大利

16.2.4

Spain

西班牙

16.2.5

The United Kingdom

英国

16.3

Japan

日本

16.3.1

MHLW

Appendix

附录

17.1

Bibliography

参考书目

17.2

Acronyms and Abbreviations

缩略语

17.3

Report Methodology

报告方法

DelveInsight Capabilities

DelveInsight功能

Disclaimer

免责声明

Related Reports